The term human papillomavirus encompasses a family of DNA viruses that are sexually transmittable and may cause either benign or malignant lesions. They are the leading cause of cervical cancer (CC), with approximately 90% of CC cases attributable to HPV, as well as a major contributor to anogenital and head and neck cancers although many patients infected with HPV will never develop any related symptoms or disease. The prevalence of any form of genital HPV in non-elderly adults in the U.S. is 42.5%, with the slightly higher prevalence in men. While there are over 40 different HPV types that may infect the genital tract, two (types 16 and 18) are associated with 66% of CC cases and two (6 and 11) cause 90% of anogenital warts.

This learning activity has been designed to bring HCPs’ knowledge of HPV vaccination and associated disease prevention up to date and to improve their competence and performance in identifying those who would benefit from vaccination.

Faculty introduction, disclosures

Epidemiology, pathophysiology, and risks associated with HPV Statistics – snapshots and trends Transmission Genotypes: The most prevalent oncogenic and STD-related HPV-related disease pathophysiology: Replication cycle, natural history, and tissue tropism Complications and related diseases in females, males Detection and the role of screening

HPV Vaccination Individual vaccination rationale, population-level goals Commercially available formulations and place(s) in therapy Efficacy, immunogenicity, and safety HPV vaccination recommendations: Indications, ages, schedule, missed doses Barriers to higher vaccination rates: Parental concerns, education, at-risk populations Strategies to improve vaccination rates Patient case(s)

Summary and Conclusion

By the end of the session the participant will be able to:

• Recall the epidemiology and complications of HPV.
• Describe the strains associated with the development of complications and disease and their related pathophysiologic processes.
• Discuss current U.S. HPV vaccination recommendations and apply them to patient cases.
• List current challenges to the prevention of HPV and high-risk groups.

ACCME Activity #201718491

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Elizabeth Lorde-Rollins, MD, MSc, Attending Obstetrician-Gynecologist, Good Samaritan Hospital, has no relevant financial disclosures.

Disclosure of Educational Planner: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Disclosure of Peer Reviewers:
Daron Brown, MD, has received financial compensation from consulting work and/or research grants from Merck and PDS, Inc.

W. Martin Kast, MD, has received financial compensation from consulting work from Brooklyn Therapeutics, AOV, Onconetics, Karma, Kiromics, Nutcracker, IMV, and Repetoire

Commercial Support Disclosure: This activity is supported by an educational grant from MERCK.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version